Porst H
Neuer Jungfernstieg 6a, 20354 Hamburg, Germany.
Int J Impot Res. 2000 Oct;12 Suppl 4:S91-S100. doi: 10.1038/sj.ijir.3900585.
Thirty percent of males afflicted with erectile dysfunction (ED) do not respond to oral drugs, another 15% reveal contraindications to currently available therapy, and a subset of patients actually prefer injection therapy due to its predictable short time-to-onset of erection and reliable rigidity compared to oral drugs. This paper provides both a historical and current perspective on intracavernosal therapy and reviews the popular injectable therapeutic agents that are currently used for the treatment of ED. Emphasis is placed on the efficacy, mechanism of action and side effect profiles of approved and experimental injectable pharmacotherapy for ED. International Journal of Impotence Research (2000) 12, Suppl 4, S91-S100.
30%患有勃起功能障碍(ED)的男性对口服药物无反应,另有15%显示出对现有治疗的禁忌症,而且一部分患者实际上更喜欢注射疗法,因为与口服药物相比,其勃起起效时间可预测且短,硬度可靠。本文提供了关于海绵体内注射疗法的历史和当前观点,并综述了目前用于治疗ED的常用注射治疗药物。重点介绍了已批准和实验性的ED注射药物治疗的疗效、作用机制和副作用情况。《国际阳痿研究杂志》(2000年)12卷,增刊4,S91 - S100。